Image Source : Business Upturn
1. Earnings Shock Triggers Sharp Sell-Off
Shares of midcap pharma firm Blue Jet Healthcare plunged 10% on July 22, hitting a low of Rs 906.15 on the NSE.
-
- Q1FY26 net profit dropped 17% quarter-on-quarter to Rs 91 crore
-
- EBITDA fell 13.1% to Rs 121 crore, with margins contracting over 700 basis points
-
- The decline was attributed to a one-off inventory charge
2. Revenue Growth Offers a Silver Lining
-
- Revenue rose 4.4% sequentially to Rs 354 crore
-
- Year-on-year comparison shows more than 100% growth from Rs 162 crore
-
- Analysts noted adjusted EBITDA and PAT were in line with expectations
3. Brokerages Remain Optimistic Despite Volatility
-
- Macquarie maintained an ‘Outperform’ rating with a target price of Rs 1,000
-
- Implies a potential upside of 10.35% from current levels
-
- Management hinted at upcoming launches in the contrast media segment
4. Investment Outlook and Risk Factors
-
- The stock’s correction may offer a tactical entry point for long-term investors
-
- Volatility remains a concern amid broader midcap weakness
-
- Analysts advise monitoring product pipeline execution and margin recovery
Sources: Zee Business, Economic Times, Reuters India, Investing.com, Blue Jet Healthcare Q1FY26 Earnings Release July 2025, Macquarie Research Note
Advertisement
Advertisement